Navigation Links
Novavax Reports First Quarter 2008 Financial Results
Date:5/9/2008

uenza vaccine program is planned in

older adult subjects commencing in the fourth quarter of 2008. The

intent of this head-to-head trial is to evaluate the immunogenicity of

the seasonal influenza VLP vaccine candidate as compared with that of

an approved, marketed vaccine in the older adult population.

-- Continued to advance two additional new vaccine discovery programs, one

for Varicella Zoster (Shingles) and a second for an undisclosed disease

target with the goal of progressing both of these candidates through

proof of concept animal studies during the next two quarters.

-- Enhanced VLP technology capabilities by developing a new approach in

creating VLPs that expands our ability to apply VLPs to a broader

number of potential vaccine disease targets.

-- Announced the completion of construction for our GMP pilot plant in the

Company's Rockville, Maryland headquarters with a ribbon cutting

ceremony held on May 1, 2008. This facility will showcase the

capability of our ready to use and disposable production technology in

a relatively low cost environment.

-- Progressed the collaboration with GE Healthcare to develop and market a

pandemic influenza vaccine manufacturing solution for selected

international countries.

-- Completed the sale of assets related to Estrasorb in the United States,

Canada and Mexico to Graceway Pharmaceuticals, LLC ("Graceway") in

February 2008. As part of that sale, Novavax entered into a supply

agreement with Graceway which requires the Company to manufacture

additional units of Estrasorb, with final delivery expected in mid-

2008.

"We continue to make solid progress in our clinical development programs and currently are on track to achieve our plans for 2008," said Novavax Chief Executive Officer Dr. Rahul Singhvi. "By th
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Decision Resources Group finds ... directors in the United States ... market penetration will be the level of savings ... the expected lower cost to patients. Payers plan ... meet their pricing expectations in order to encourage ...
(Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
(Date:7/30/2014)... Sales Horizons, a leader in sales ... training programs for companies engaged in complex B2B sales. ... thousands of salespeople over 25 years in market-leading Fortune ... be customized to address the unique sales challenges of ... training program consists of two parts: Mastering the ...
(Date:7/30/2014)... 30, 2014 July 30, 2014. ... biotechnology firm that provides DNA-based authentication and security solutions ... Vice President of Life Sciences, a newly created position, ... Dr. Hogan will lead APDN’s drive to build its ... biotech and healthcare customers, provide guidance to APDN’s R&D ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... 26 Medivation, Inc. (Nasdaq: MDVN) today announced ... Time tomorrow, Tuesday, October 27, to discuss partnering plans for ... testing for the treatment of prostate cancer. , ... call on Tuesday, October 27, at 8:30 a.m. Eastern Time ...
... Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... accelerating the development and enhancing the value of oncology ... Research & Development, a Division of Janssen Pharmaceutica NV, ... in Champions, Biomerk Tumorgraft(TM) platform. , "We ...
... ... presented this week at the annual meeting of the Society for Neuroscience ... a stroke. In prior conferences, data from the University of Wisconsin-Milwaukee ... Quincy Bioscience Quincy Bioscience is a partner in the research ...
Cached Biology Technology:Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 2Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 3Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 2Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 3
(Date:7/29/2014)... As the climate warms and sea ice retreats, the ... season of increasingly open water which is predicted to ... of this century. Storms thus have the potential to ... a new and unpredictable element to the region. , A ... waves in the middle of the Arctic Ocean, and ...
(Date:7/29/2014)... a restaurant, don,t blame yourself; blame the menu. What ... want and more to do with a menu,s layout and ... over 300 diners, the Cornell study published this month in ... when it comes to what you order for dinner, two ... how you imagine it will taste. , First, any food ...
(Date:7/29/2014)... Scale plays a major role in locomotion. Swimming microorganisms, ... small inertial forces compared to the viscous forces exerted ... self-propulsion a major challenge. Now, scientists have found that ... is opposite to that induced by a viscoelastic fluid. ... by Franois Nadal from the Alternative Energies and ...
Breaking Biology News(10 mins):Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3Menu secrets that can make you slim by design 2Optimum inertial self-propulsion design for snowman-like nanorobot 2
... Scripps Health announced today it has launched an innovative ... help determine the causes of idiopathic human diseases -- those ... or are unresponsive to standard treatments. The use of ... and treating rare medical cases. Whole genome sequencing provides ...
... identified and mapped the chemical structure of molecules used by ... growth of reef-building coral. Chemicals found on the surfaces ... coral, suggesting that competition with these macroalgae could be a ... of coral reefs. Seaweed growth on coral reefs ...
... difficult to measure accurately each nation,s contribution of carbon dioxide ... ground as coal, gas, and oil, and these fuels are ... generate the energy that is used to make products. In ... where they are consumed. A team led by Carnegie,s Steven ...
Cached Biology News:Scripps launches whole genome sequencing study to find root causes of idiopathic diseases 2Scripps launches whole genome sequencing study to find root causes of idiopathic diseases 3Study identifies molecules used by certain species of seaweed to harm corals 2Study identifies molecules used by certain species of seaweed to harm corals 3Study identifies molecules used by certain species of seaweed to harm corals 4Links in the chain: Global carbon emissions and consumption 2
... Science FLA-5100 imaging system allows imaging of ... 40 x 46cm at a pixel size ... is especially suitable for protein electrophoresis in ... for genomics., Fuji s FLA-5100 includes four ...
... Biometras T1 Thermocycler provides high speed ... been optimized with a TGradient Thermocycler can ... thermocycler comes with a silver block for ... for 384 well plates or in-situ applications ...
... inL10 Workstation from Caliper represents a revolutionary ... the first time the ability to generate ... to changing conditions. In addition, each ... due to changes in temperature, and offers ...
... Vivaclear centrifugal filters are disposable microfiltration devices ... samples in the range 100 l to 500 ... rotors accepting 2.2 ml centrifuge tubes. Product Features: ... pore size Low hold up volume ...
Biology Products: